Lotus Eye Hospital and Institute Limited has formally notified stock exchanges about an upcoming board meeting to discuss a significant corporate restructuring decision. The healthcare company, which operates multiple eye care facilities across South India, has scheduled this important deliberation for March 17, 2026.

Board Meeting Details and Regulatory Compliance

The board meeting has been convened in accordance with Regulation 29 of SEBI (LODR) Regulations, 2015, demonstrating the company's commitment to regulatory compliance and transparency. The meeting notification was sent to both major stock exchanges on March 12, 2026.

Delisting Proposal Scope

The proposed delisting specifically targets the company's equity shares listed on the National Stock Exchange of India Limited (NSE). This voluntary delisting initiative falls under the provisions of SEBI (Delisting of Equity Shares) Regulations, 2021, which provides a structured framework for companies seeking to exit from stock exchanges.

The company has emphasized that this proposal affects only its NSE listing, while its presence on BSE Limited will remain unchanged. This selective approach allows the company to maintain market accessibility while potentially streamlining its exchange obligations.

Continued Market Presence

Lotus Eye Hospital and Institute Limited has assured stakeholders that it will continue its listing on BSE Limited following the potential NSE delisting. BSE Limited operates as a stock exchange with nationwide trading terminals, ensuring that investors will retain access to trade the company's shares.

Corporate Communication

The formal notification was signed by Prathish S, who serves as the Company Secretary and Compliance Officer. The communication was digitally signed on March 12, 2026, reflecting modern corporate governance practices and ensuring document authenticity.

The company operates multiple locations across South India, including facilities in Coimbatore, Salem, Tirupur, Mettupalayam, Kochi, and Karur, indicating its established presence in the regional healthcare sector. This extensive network positions the company as a significant player in specialized eye care services across these markets.

Lotus eye hospital And Institute Limited has been penalized by both major Indian stock exchanges for regulatory non-compliance. The healthcare company disclosed that BSE Limited and National Stock Exchange of India Limited have each imposed fines of Rs 2,17,120, inclusive of GST, for violations under SEBI listing regulations.

Regulatory Violation Details

The penalty stems from non-compliance with Regulation 17(1A) of the SEBI (LODR) Regulations, 2015. The company received official communication regarding this action through email and letter dated February 27, 2026.

Remedial Actions Taken

Lotus Eye Hospital And Institute Limited has taken steps to address the compliance issue. The company rectified the non-compliance through shareholder approval obtained via postal ballot, with resolutions deemed to have been passed on January 17, 2026.

The company's board of directors acknowledged the non-compliance comments at their meeting held on February 11, 2026. Subsequently, the board's observations were communicated to both stock exchanges on February 12, 2026.

Financial Impact Assessment

According to the company's disclosure, the regulatory penalty will not have any material impact on its financial operations. The healthcare institution has also clarified that stock exchanges had previously levied fines up to the quarter ended September 30, 2025, which the company has duly paid.

Corporate Background

The present penalty specifically pertains to the quarter ended December 31, 2025. The company operates multiple healthcare facilities across Tamil Nadu and Kerala, with locations in Coimbatore, Salem, Tirupur, Mettupalayam, Kochi, and Karur, specializing in eye care services.